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Guy Neff, M.D., Carroll B. Leevy, M.D.,* Samuel Sigal, M.D., Muhammad Y. Sheikh, M.D., Kimberly Beavers, M.D.,
Todd Frederick, M.D., Lewis Teperman, M.D., Donald Hillebrand, M.D., Shirley Huang, M.S., Kunal Merchant, Ph.D.,
Audrey Shaw, Ph.D., Enoch Bortey, Ph.D., and William P. Forbes, Pharm.D.

A bs t r ac t
Background

Hepatic encephalopathy is a chronically debilitating complication of hepatic cirrhosis. The efficacy of rifaximin, a minimally absorbed antibiotic, is well documented
in the treatment of acute hepatic encephalopathy, but its efficacy for prevention of
the disease has not been established.
Methods

In this randomized, double-blind, placebo-controlled trial, we randomly assigned
299 patients who were in remission from recurrent hepatic encephalopathy resulting from chronic liver disease to receive either rifaximin, at a dose of 550 mg twice
daily (140 patients), or placebo (159 patients) for 6 months. The primary efficacy
end point was the time to the first breakthrough episode of hepatic encephalopathy. The key secondary end point was the time to the first hospitalization involving
hepatic encephalopathy.
Results

Rifaximin significantly reduced the risk of an episode of hepatic encephalopathy,
as compared with placebo, over a 6-month period (hazard ratio with rifaximin,
0.42; 95% confidence interval [CI], 0.28 to 0.64; P<0.001). A breakthrough episode
of hepatic encephalopathy occurred in 22.1% of patients in the rifaximin group, as
compared with 45.9% of patients in the placebo group. A total of 13.6% of the patients in the rifaximin group had a hospitalization involving hepatic encephalopathy, as compared with 22.6% of patients in the placebo group, for a hazard ratio of
0.50 (95% CI, 0.29 to 0.87; P = 0.01). More than 90% of patients received concomitant lactulose therapy. The incidence of adverse events reported during the study
was similar in the two groups, as was the incidence of serious adverse events.
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Conclusions

Over a 6-month period, treatment with rifaximin maintained remission from hepatic encephalopathy more effectively than did placebo. Rifaximin treatment also
significantly reduced the risk of hospitalization involving hepatic encephalopathy.
(ClinicalTrials.gov number, NCT00298038.)
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A

pproximately 5.5 million persons in
the United States have hepatic cirrhosis, a
major cause of complications and death.1-3
Hepatic encephalopathy, a complication of hepatic cirrhosis, imposes a formidable burden on
patients, their families, and the health care system.1,4 Overt episodes of hepatic encephalopathy
are debilitating, can occur without warning, render the patient incapable of self-care, and frequently result in hospitalization.1,4 In 2003, more
than 40,000 patients were hospitalized with hepatic encephalopathy, a number that increased to
over 50,000 in 2004.4 Although the occurrence of
episodes of hepatic encephalopathy appears to be
unrelated to the cause of cirrhosis,5 increases in
the frequency and severity of such episodes predict an increased risk of death.6,7
Hepatic encephalopathy is a neuropsychiatric
syndrome for which symptoms, manifested on a
continuum, are deterioration in mental status,
with psychomotor dysfunction, impaired memory, increased reaction time, sensory abnormalities,
poor concentration, disorientation, and — in
severe forms — coma.1,7,8 The clinical diagnosis
of overt hepatic encephalopathy is based on two
concurrent types of symptoms: impaired mental status, as defined by the Conn score (also
called West Haven criteria) (on a scale from 0 to 4,
with higher scores indicating more severe impairment),9 and impaired neuromotor function.1,10
The Conn score is recommended by the Working
Party on Hepatic Encephalopathy8 for assessment
of overt hepatic encephalopathy in clinical trials.
Signs of neuromotor impairment include hyperreflexia, rigidity, myoclonus, and asterixis (a coarse,
myoclonic, “flapping” muscle tremor), which is
measured with the use of an asterixis severity
scale.10-12
Most therapies for hepatic encephalopathy
focus on treating episodes as they occur and are
directed at reducing the nitrogenous load in the
gut, an approach that is consistent with the hypothesis that this disorder results from the systemic accumulation of gut-derived neurotoxins,
especially ammonia, in patients with impaired
liver function and portosystemic shunting.2,3,13
The current standard of care for patients with
hepatic encephalopathy, treatment with nonabsorbable disaccharides lactitol or lactulose, decreases the absorption of ammonia through cathartic effects and by altering colonic pH.14
In an open-label, single-site study, Sharma et al.
reported that lactulose, as compared with placebo,
1072
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was effective in the prevention of overt hepatic
encephalopathy.15 In that study, 125 patients who
had recovered from a recent episode of hepatic
encephalopathy were randomly assigned, in a 1:1
ratio, to receive either lactulose or placebo for up
to 20 months. During a median study period of
14 months, the proportion of patients with episodes was smaller in the lactulose group than in
the placebo group (19.6% vs. 46.8%, P = 0.001).
However, side effects of lactulose therapy — including an excessively sweet taste and gastrointestinal side effects such as bloating, flatulence,
and severe and unpredictable diarrhea possibly
leading to dehydration — result in frequent noncompliance.16-18
In general, the oral antibiotics neomycin, par
omomycin, vancomycin, and metronidazole have
been effectively used, with or without lactulose,
to reduce ammonia-producing enteric bacteria
in patients with hepatic encephalopathy.14,16,17
However, some oral antibiotics are not recommended for long-term use because of nephrotoxicity, ototoxicity, and peripheral neuropathy19,20
and are specifically contraindicated in patients
with liver disease.19,21,22
Rifaximin is a minimally absorbed oral antimicrobial agent that is concentrated in the gastrointestinal tract, has broad-spectrum in vitro activity
against gram-positive and gram-negative aerobic
and anaerobic enteric bacteria, and has a low risk
of inducing bacterial resistance.23-25 In randomized studies, rifaximin was more effective than
nonabsorbable disaccharides and had efficacy that
was equivalent to or greater than that of other
antibiotics used in the treatment of acute hepatic
encephalopathy.26-39 Furthermore, with minimal
systemic bioavailability, rifaximin may be more
conducive to long-term use than other, more bioavailable antibiotics with detrimental side effects.
In this phase 3, multicenter, randomized, double-blind, placebo-controlled study conducted over
a 6-month period, we evaluated the efficacy and
safety of rifaximin, used concomitantly with lactulose, for the maintenance of remission from episodes of hepatic encephalopathy in outpatients
with a recent history of recurrent, overt hepatic
encephalopathy.

Me thods
Study Patients

Eligibility criteria were an age of at least 18 years,
at least two episodes of overt hepatic encepha
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lopathy (Conn score, ≥2)9,12 associated with hepatic
cirrhosis during the previous 6 months, remission
299 Patients underwent randomization
(Conn score, 0 or 1) at enrollment, and a score of
25 or less on the Model for End-Stage Liver Disease
(MELD) scale40 (on which scores can range from
6 to 40, with higher scores indicating more severe disease). Episodes of hepatic encephalopathy
159 Were assigned to
140 Were assigned to
that were precipitated by gastrointestinal hemorreceive placebo
receive rifaximin
rhage requiring transfusion of at least 2 units of
blood, by medication use, by renal failure requiring dialysis, or by injury to the central nervous
159 Were included in the intention140 Were included in the intentionsystem were not counted as previous episodes.
to-treat and safety populations
to-treat and safety populations
Exclusion criteria included the expectation of
liver transplantation within 1 month after the
screening visit and the presence of conditions
93 Discontinued the study drug
52 Discontinued the study drug
that are known precipitants of hepatic encephal69 (43.4%) Had as primary reason
28 (20.0%) Had as primary reason
opathy (including gastrointestinal hemorrhage and
breakthrough HE
breakthrough HE
24 (15.1%) Had as primary reason
24 (17.1%) Had as primary reason
the placement of a portosystemic shunt or a trans
nonbreakthrough event
nonbreakthrough event
jugular intrahepatic portosystemic shunt) within
7 (4.4%) Had adverse event
8 (5.7%) Had adverse event
9 (5.7%) Requested withdrawal
6 (4.3%) Requested withdrawal
3 months before the screening visit, chronic renal
3 (1.9%) Died
6 (4.3%) Died
insufficiency (creatinine level, >2.0 mg per decili3 (1.9%) Met an exclusion
1 (0.7%) Met an exclusion
criterion
criterion
ter [177 μmol per liter]) or respiratory insuffi1 (0.6%) Underwent liver
3 (2.1%) Had other reason
ciency, anemia (hemoglobin level, <8 g per decitransplantation
1 (0.6%) Had other reason
liter), an electrolyte abnormality (serum sodium
level, <125 mmol per liter; serum calcium level,
Figure 1. Randomization and Follow-up of the Intention-to-Treat Population.
>10 mg per deciliter [2.5 mmol per liter]; or poRETAKE:
1st
AUTHOR:
(Forbes)
HE denotes
hepaticBass
encephalopathy.
tassium level, <2.5 mmol per liter), intercurrent
2nd
infection, or active spontaneous bacterial peritoFIGURE: 1 of 3
3rd
Revised
nitis. All patients or their legally authorized repARTIST: ts
resentatives provided written informed consent. International), and ClinStar Europe under theSIZE
4 col
TYPE: Line
Combo
4-C
H/T
supervision of
Salix representatives,
who
also22p3
AUTHOR,participated
PLEASE NOTE: in the
Study Design and Procedures
analyzed the data. All authors
Figure has been redrawn and type has been reset.
andcheck
the carefully.
writing of the
The protocol was approved by the institutional interpretation of the dataPlease
review board or ethics committee at each center manuscript. An editorial consultant was paid by
JOB: 36212
ISSUE: 03-25-10
and was conducted in accordance with Interna- Salix to assist in the revision of subsequent drafts
tional Conference on Harmonisation guidelines before submission. All authors vouch for the
and other applicable laws and regulations. The completeness and veracity of the data and data
study included a screening visit, an observation analyses.
period between the screening visit and enrollment, and a 6-month treatment phase. On day 0, Efficacy and Safety Assessments
eligible patients were randomly assigned, in a 1:1 Clinic visits occurred on days 7 and 14 and every
ratio, to receive either 550 mg of rifaximin or 2 weeks thereafter through day 168 (end of the
placebo, twice daily, for 6 months or until they treatment period), with optional visits on days
discontinued the study drug because of a break- 42, 70, 98, 126, and 154. Patients were monitored
through episode of hepatic encephalopathy or an- by telephone during the weeks without clinic visother reason. Concomitant administration of lactu- its. Assessments included the Conn score and
asterixis grade. Conn scores are defined as follose was permitted during the study.
The study protocol was designed by represen- lows: 0, no personality or behavioral abnormality
tatives of Salix Pharmaceuticals and the academic detected; 1, trivial lack of awareness, euphoria or
authors. Data were collected by the principal in- anxiety, shortened attention span, or impairment
vestigators at each center (see the Appendix) and of ability to add or subtract; 2, lethargy, disorienwere monitored by Omnicare Clinical Research, tation with respect to time, obvious personality
Clinical Trial Management Services (now Chiltern change, or inappropriate behavior; 3, somnolence
n engl j med 362;12
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or semistupor, responsiveness to stimuli, confusion, gross disorientation, or bizarre behavior; and
4, coma.9 Asterixis was assessed according to
standard practice, by asking patients to extend
their arms with wrists flexed backward and fingers open for 30 seconds or more.11,39 Asterixis
was then graded as follows: 0, no tremors; 1, few
flapping motions; 2, occasional flapping motions;
3, frequent flapping motions; and 4, almost continuous flapping motions.11 Investigators and site
personnel who performed assessments were
trained in order to ensure consistency across sites.
Statistical Analysis

Efficacy data were analyzed for the intention-totreat population, which included patients who received at least one dose of the study medication.
The primary efficacy end point was the time to
the first breakthrough episode of hepatic enceph-

of
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alopathy, defined as the time from the first dose
of the study drug to an increase from a baseline
Conn score of 0 or 1 to a score of 2 or more or from
a baseline Conn score of 0 to a Conn score of 1 plus
a 1-unit increase in the asterixis grade. The key
secondary efficacy end point was the time to the
first hospitalization involving hepatic encephalopathy (defined as hospitalization because of the
disorder or hospitalization during which an episode of hepatic encephalopathy occurred).
The Cox proportional-hazards model was used,
with a 2-sided test and a significance level of 0.05,
to compare the time to a breakthrough episode
between the rifaximin group and the placebo
group (after adjustment for geographic region).
Kaplan–Meier methods were used to estimate the
proportions of patients having a breakthrough
episode at successive time points during the study.
Patients who withdrew from the study early for

Table 1. Baseline Characteristics of the Patients, According to Study Group.*
Characteristic
Age — yr
Age group — no. (%)
<65 yr
≥65 yr
Male sex — no. (%)
Race or ethnic group — no. (%)†
American Indian or Alaskan native
Asian
Black or of African ancestry
Native Hawaiian or Pacific Islander
White
Other
Missing data
Duration of current remission — days
No. of HE episodes in past 6 mo — no. (%)
2
>2
Missing data
Conn score during most recent HE episode before study — no. (%)‡
1
2
3 or 4
Missing data
Time since first diagnosis of advanced liver disease — mo
MELD score — no. (%)§
≤10
11–18
19–24
Missing data

1074

Rifaximin
(N = 140)

Placebo
(N = 159)

55.5±9.6

56.8±9.2

113 (80.7)
27 (19.3)
75 (53.6)

128 (80.5)
31 (19.5)
107 (67.3)

5 (3.6)
4 (2.9)
7 (5.0)
2 (1.4)
118 (84.3)
3 (2.1)
1 (0.7)
68.8±47.7

3 (1.9)
8 (5.0)
5 (3.1)
1 (0.6)
139 (87.4)
3 (1.9)
0
73.1±51.3

97 (69.3)
43 (30.7)
0

111 (69.8)
47 (29.6)
1 (0.6)

1 (0.7)
115 (82.1)
23 (16.4)
1 (0.7)
51.2±49.2

2 (1.3)
130 (81.8)
26 (16.4)
1 (0.6)
60.5±64.9

34 (24.3)
94 (67.1)

48 (30.2)
96 (60.4)

12 (8.6)

14 (8.8)

0
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nejm.org

1 (0.6)

march 25, 2010

The New England Journal of Medicine
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 15, 2015. For personal use only. No other uses without permission.
Copyright © 2010 Massachusetts Medical Society. All rights reserved.

Rifaximin Treatment in Hepatic Encephalopathy

Table 1. (Continued.)
Characteristic

Rifaximin
(N = 140)

Placebo
(N = 159)

Lactulose use at baseline — no. (%)

128 (91.4)

145 (91.2)

Lactulose‖

128 (91.4)

145 (91.2)

Spironolactone

Concomitant medication use during the study — no. (%)¶
100 (71.4)

100 (62.9)

Furosemide

84 (60.0)

94 (59.1)

Propranolol

35 (25.0)

35 (22.0)

Omeprazole

29 (20.7)

35 (22.0)

Pantoprazole

25 (17.9)

27 (17.0)

Ursodiol

22 (15.7)

22 (13.8)

Multivitamins

21 (15.0)

23 (14.5)

Folic acid

20 (14.3)

9 (5.7)

Esomeprazole magnesium

20 (14.3)

22 (13.8)

Nadolol

16 (11.4)

19 (11.9)

Acetaminophen

14 (10.0)

20 (12.6)

Insulin glargine

12 (8.6)

16 (10.1)

* Plus–minus values are means ±SD. Differences between groups for each characteristic were tested for significance with
Fisher’s exact test for nominal variables and the t-test for continuous variables. Only sex and folic acid use differed significantly between groups (P = 0.02 for each comparison). HE denotes hepatic encephalopathy.
† Race or ethnic group was self-reported.
‡ The Conn score can range from 0 to 4, with higher scores indicating more severe impairment.
§ The Model for End-Stage Liver Disease (MELD) score can range from 6 to 40, with higher scores indicating more severe disease.
¶ The listed medications are those that were reportedly being used concomitantly with the study medication in 5% or
more of patients in either group. Use of the following medications was prohibited during the study: benzodiazepines or
benzodiazepine-like compounds, nonabsorbable disaccharides except lactulose, psyllium-containing intestinal regulators, warfarin-type anticoagulant agents, branched-chain amino acids, l-ornithine-l-aspartate, antibiotic therapy other
than the study medication, and narcotic agents, psychotropic agents, and other psychoactive or neuroactive agents
with the exception of gabapentin or pregabalin, sleep aids, and antihistamines used before the screening visit and administered at a constant dose throughout the study.
‖ Concomitant lactulose use (during the study) was coincidentally reported in the same number of patients as those reported to have been receiving lactulose at baseline. During the study, three of the patients who had been receiving
lactulose discontinued the therapy, and another three patients started lactulose (one in the rifaximin group and two in
the placebo group).

reasons other than the development of hepatic
encephalopathy (e.g., another adverse event or the
subject’s request) were contacted 6 months after
randomization to determine whether a breakthrough episode of hepatic encephalopathy had
occurred since withdrawal. Data for patients who
did not have breakthrough hepatic encephalopathy before day 168 were censored at the time of
last contact or on day 168, whichever was earlier.
Data for patients who did not have a hospitalization involving hepatic encephalopathy before day
168 were censored at the time of study termination or on day 168, whichever was earlier. The
same statistical methods were used to analyze
the key secondary end point: time to the first hospitalization involving hepatic encephalopathy.
The primary efficacy end point was evaluated
n engl j med 362;12

in subgroups of patients according to the following characteristics: geographic region, sex, age,
race or ethnic group, baseline MELD score, baseline Conn score, diabetes at baseline, duration of
current verified remission, number of episodes of
hepatic encephalopathy within the 6-month period before randomization, lactulose use at baseline, and previous placement of a transjugular intrahepatic portosystemic shunt.
Sample-size calculations were based on an
assumption of breakthrough episodes of hepatic
encephalopathy occurring in 50% and 70% of patients receiving rifaximin and placebo, respectively.
These calculations indicated that to show the superiority of rifaximin over placebo with a statistical power of more than 80%, we would need to
evaluate 100 patients per group. Safety data were
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Patients (%)

60
Placebo

40
20
0

Hazard ratio with rifaximin, 0.42 (95% CI, 0.28–0.64)
P<0.001
0

28

56

84

112

140

168

Days since Randomization

B Time to First HE-Related Hospitalization (Key Secondary End Point)
100
Rifaximin

Patients (%)

80
Placebo

60
40
20
0

Hazard ratio with rifaximin, 0.50 (95% CI, 0.29–0.87)
P=0.01
0
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56

84

112

140

168

Days since Randomization

Figure 2. Kaplan–Meier Estimates of the Primary and Key Secondary End
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Safety assessments included adverse events, seri36212
ISSUE: 03-25-10
ous adverse events, and adverse events specifically
consisting of infection, including respiratory and
gastrointestinal infections and their symptoms.
Infections are of special interest because of known
potential side effects of systemic antibiotics, as
a drug class, and known effects of rifaximin.

R e sult s
Study Patients

A total of 299 patients in the United States (205
patients), Canada (14 patients), and Russia (80 patients) were randomly assigned to receive a study
drug at 70 investigative sites. The study began on
December 5, 2005, and was completed on August
15, 2008. All patients received at least one dose of
1076
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study medication and underwent at least one safety assessment after enrollment. Therefore, all patients were included in both the intention-to-treat
population and the safety population (Fig. 1). As
specified by the study protocol, the study drug
was discontinued at the time of the first breakthrough episode of hepatic encephalopathy. The
incidence of early withdrawal for any reason other than a breakthrough episode was similar in
the rifaximin group and the placebo group.
Baseline characteristics were similar in the
two groups (Table 1). Patients were predominantly
white, male, and younger than 65 years of age. All
patients had a history of overt episodic hepatic
encephalopathy associated with advanced liver disease, diagnosed on the basis of two or more episodes of overt hepatic encephalopathy (Conn score,
≥2) within 6 months before the screening visit.
Similar percentages of patients in the placebo
group (91.2%) and rifaximin group (91.4%) were
receiving lactulose at baseline, and the mean daily
doses of lactulose during the study period were
stable (see the Supplementary Appendix, available
with the full text of this article at NEJM.org).
Commonly used concomitant medications were
those that would be expected for patients with
chronic liver disease (Table 1).
The mean (±SD) duration of treatment was
130.3±56.5 days in the rifaximin group and
105.7±62.7 days in the placebo group. The rate
of compliance, defined as use of at least 80% of
the dispensed tablets, was high in both study
groups (84.3% in the rifaximin group and 84.9%
in the placebo group).

A Time to First Breakthrough HE Episode (Primary End Point)

80

of

Breakthrough Episodes

Breakthrough episodes of hepatic encephalopathy
were reported in 31 of 140 patients in the rifaximin
group (22.1%) and 73 of 159 patients in the placebo
group (45.9%). Figure 2A shows the time to a breakthrough episode (the primary end point). The hazard ratio for the risk of a breakthrough episode in
the rifaximin group, as compared with the placebo
group, was 0.42 (95% confidence interval [CI], 0.28
to 0.64; P<0.001), reflecting a relative reduction in
the risk of a breakthrough episode by 58% with rifaximin as compared with placebo during the
6-month study period. These data suggest that four
patients would need to be treated with rifaximin for
6 months to prevent one episode of overt hepatic
encephalopathy. The degree to which rifaximin reduced the risk of a breakthrough episode was consistent across subgroups (Fig. 3).
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Subgroup

Rifaximin
(N=140)

Placebo
(N=159)

P Value for
Treatment
Effect

Hazard Ratio (95% CI)

no. of patients
Region
United States and Canada
Russia
Sex
Male
Female
Age
<65 yr
≥65 yr
Race or ethnic group
White
Other
MELD score
≤10
11–18
19–24
Conn score
0
1
Lactulose use at baseline
Yes
No
Diabetes
Yes
No
Duration of remission
≤90 Days
>90 Days
No. of HE episodes in previous 6 mo
2
>2
TIPS
Yes
No
Time to first breakthrough HE episode

101
39

118
41

<0.001
0.03

75
65

107
52

0.009
<0.001

113
27

128
31

<0.001
0.01

118
22

139
20

<0.001
0.046

34
94
12

48
96
14

0.01
<0.001
0.21

93
47

107
52

0.002
0.003

128
12

145
14

<0.001
0.33

44
96

56
103

0.01
<0.001

100
39

110
48

<0.001
0.04

97
43

111
47

0.002
0.003

12
128
140

20
139
159

0.03
<0.001
<0.001
0.0

0.5

1.0

1.5

Rifaximin Better

2.0

2.5

3.0

3.5

Placebo Better

Figure 3. Results of the Subgroup Analysis.
Hazard ratios for the risk of a breakthrough
episode of hepatic encephalopathy (HE)
during the
6-month study period are shown for the
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Safety

The incidence of adverse events reported during
the study was similar in the rifaximin group
(80.0%) and the placebo group (79.9%), as was the
incidence of the more common serious adverse
events (Table 2). Among the adverse events related
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to infection, Clostridium difficile infection was reported in two patients in the rifaximin group and
none in the placebo group; both affected patients
had several concurrent risk factors for C. difficile
infection, such as advanced age, numerous recent
hospitalizations involving multiple courses of antibiotic therapy, and use of the proton-pump inhibitor pantoprazole. In both patients, rifaximin
therapy was continued concomitantly with treatment for the infection, from which they fully recovered.
A total of 20 patients died during the study (9
in the rifaximin group and 11 in the placebo
group). Most of the deaths were attributed to
conditions associated with disease progression:
five patients in each of the two groups had hepatic cirrhosis, decompensated cirrhosis, hepatic
failure, alcoholic cirrhosis, or end-stage liver failure, and two patients in each of the two groups
had esophageal varices or hemorrhage from esoph-
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ageal varices. Nearly all the patients who died had
had evidence at baseline, apart from hepatic encephalopathy, of decompensated liver cirrhosis
(i.e., portal hypertension, ascites or edema, or
jaundice), which is associated with a reduced
probability of survival.41,42

Discussion
The prevention of episodes of hepatic encephalopathy is an important goal in the treatment of patients with liver disease,1,2,4,6,7 especially since
symptoms of overt encephalopathy are debilitating and decrease the ability for self-care, leading
to improper nutrition and nonadherence to a therapeutic regimen, which in turn leads to severe
symptoms, frequent hospitalizations, and a poor
quality of life. Our study showed that the use of
rifaximin reduced the risk of a breakthrough episode of hepatic encephalopathy during a 6-month

Table 2. Adverse Events, According to Study Group.*
Rifaximin
(N = 140)

Event

Placebo
(N = 159)
number (percent)

Adverse events†
Any event
Nausea
Diarrhea
Fatigue
Peripheral edema
Ascites
Dizziness
Headache
Muscle spasms
Pruritus
Abdominal pain
Abdominal distention
Anemia
Vomiting
Insomnia
Depression
Cough
Constipation
Upper abdominal pain
Pyrexia
Back pain
Arthralgia
Dyspnea
Urinary tract infection
Rash
Asthenia

1078

112 (80.0)
20 (14.3)
15 (10.7)
17 (12.1)
21 (15.0)
16 (11.4)
18 (12.9)
14 (10.0)
13 (9.3)
13 (9.3)
12 (8.6)
11 (7.9)
11 (7.9)
10 (7.1)
10 (7.1)
10 (7.1)
10 (7.1)
9 (6.4)
9 (6.4)
9 (6.4)
9 (6.4)
9 (6.4)
9 (6.4)
8 (5.7)
7 (5.0)
4 (2.9)

n engl j med 362;12
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127 (79.9)
21 (13.2)
21 (13.2)
18 (11.3)
13 (8.2)
15 (9.4)
13 (8.2)
17 (10.7)
11 (6.9)
10 (6.3)
13 (8.2)
12 (7.5)
6 (3.8)
14 (8.8)
11 (6.9)
8 (5.0)
11 (6.9)
10 (6.3)
8 (5.0)
5 (3.1)
10 (6.3)
4 (2.5)
7 (4.4)
14 (8.8)
6 (3.8)
12 (7.5)
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Table 2. (Continued.)
Rifaximin
(N = 140)

Event

Placebo
(N = 159)
number (percent)

Serious adverse events‡
Anemia
Ascites
Esophageal varices
Pneumonia
Vomiting
Generalized edema
Hepatic cirrhosis
Cellulitis
Acute renal failure
Adverse events possibly related to infection§
Bacterial peritonitis
Pneumonia
Gastrointestinal hemorrhage
Hematochezia
Bacteremia
Gastritis
Clostridium difficile infection
Sepsis

4 (2.9)
4 (2.9)
4 (2.9)
4 (2.9)
3 (2.1)
3 (2.1)
3 (2.1)
3 (2.1)
2 (1.4)

0
4 (2.5)
2 (1.3)
1 (0.6)
0
2 (1.3)
6 (3.8)
2 (1.3)
4 (2.5)

2 (1.4)
4 (2.9)
1 (0.7)
2 (1.4)
1 (0.7)
2 (1.4)
2 (1.4)
0

4 (2.5)
1 (0.6)
3 (1.9)
1 (0.6)
2 (1.3)
0
0
2 (1.3)

* The incidences of adverse events did not differ significantly between the two study groups (P>0.05 for all comparisons),
according to Fisher’s exact test.
† The adverse events listed were reported in 5% or more of the patients in either study group.
‡ The serious adverse events listed were reported in 2% or more of the patients in either study group (hepatic encepha
lopathy not included).
§ The adverse events possibly related to infection that are listed were reported in two or more patients in either study
group. These were of special interest because of known potential side effects of the use of systemic antibiotics, as a
drug class, and known effects of rifaximin.

period among patients in remission who had a recent history of recurrent overt hepatic encephalop
athy (≥2 episodes within the previous 6 months)
before enrollment. The reduced risk was seen
across subgroups, further showing the consistency
of the results, which expand previously reported
findings of the efficacy of rifaximin in the treatment of overt hepatic encephalopathy.26-34,39
The current study differs from previous randomized studies in that it examined the protective effect of rifaximin against breakthrough episodes of hepatic encephalopathy rather than its
effect in the treatment of acute, overt symptoms;
the study also involved a larger group of patients
and a longer study period. In previous randomized studies, rifaximin was administered for 21
days or less26-30,32,33 or intermittently, for 14 or
15 days per month for 3 or 6 months.33,34,39
Our study shows the superiority of rifaximin
therapy over treatment with lactulose alone. More
than 90% of patients received concomitant lactun engl j med 362;12

lose during the study period, and a significant
treatment effect was noted within 28 days after
randomization. In contrast, a recent single-center, open-label study of 120 patients showed that
although lactulose therapy was more effective
than no active treatment in the prevention of
overt hepatic encephalopathy,15 the treatment effects favoring lactulose were apparent only after
approximately 4 months.
In the current, prospective study, rifaximin
therapy reduced the risk of hospitalization involving hepatic encephalopathy, reflecting the clinical
significance of our efficacy findings. Also, the
reduced risk of hospitalization supports the results of retrospective chart reviews,4,43 which have
shown that rifaximin, as compared with lactulose, is associated with a significantly lower frequency and duration of hospitalization and lower
hospital costs.
The incidences of adverse events in general and
adverse events consisting of infection in particu-
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lar were similar in the rifaximin group and the
placebo group. The safety profile of rifaximin appears to be superior to that of systemic antibiotics, particularly for patients with liver disease.31
The occurrence of nephrotoxicity and ototoxicity
with the use of aminoglycosides (e.g., neomycin
and paromomycin) and of nausea and peripheral
neuropathy with prolonged use of metronidazole
restricts their use in patients with hepatic encephalopathy.19,21,22
The risk of bacterial resistance appears to be
lower with rifaximin than with systemic antibiotics. Plasma levels of rifaximin are negligible;
therefore, bacteria outside the gastrointestinal tract
are not exposed to appreciable selective pressure.
In addition, whereas resistance to other antimicrobial agents is plasma-mediated, resistance to
rifaximin is mediated through reversible genomic
change. For chromosomally mediated mutation
and selection to result in clinically relevant resistance, the mutation cannot be lethal and cannot
significantly decrease virulence; otherwise, the
resistant trait will not be transmitted. Both in
vitro and in vivo studies of the effects of rifaxi-
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min on commensal flora suggest that rifaximinresistant organisms have low viability.25,44,45
In summary, this study shows a robust protective effect of rifaximin against episodes of
hepatic encephalopathy. Rifaximin also reduces
the risk of hospitalization involving hepatic encephalopathy.1,31
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